ProShare Advisors’s Climb Bio CLYM Stock Holding History

ProShare Advisors’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,469	Closed	-$20.6K	–	2264
2024 Q4	$20.6K	Buy	+11,469	New	+$41.5K	﹤0.01%	2255

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's CLYM Position: Q1 2025 in Review

ProShare Advisors sold out of Climb Bio (CLYM) in Q1 2025, closing a stake of 11,469 shares — an estimated $20.6K sold.

ProShare Advisors first reported a position in CLYM in Q4 2024 and held it in 1 quarter. The position peaked at $20.6K in Q4 2024. 76 funds tracked by Wall St. Rank hold CLYM as of Q1 2025.

ProShare Advisors reported no remaining Climb Bio position as of Q1 2025 after selling out during the quarter.
ProShare Advisors sold 11,469 Climb Bio shares in Q1 2025, an estimated $20.6K.
ProShare Advisors first reported a position in Climb Bio in Q4 2024 and held it in 1 quarter.
ProShare Advisors's Climb Bio position peaked at $20.6K in Q4 2024.
76 funds tracked by Wall St. Rank held Climb Bio as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.